Current Research Studies

Stanford Research Clinic

SPECIALIZING IN NOVEL AND INNOVATIVE RESEARCH APPROACHES

FOR ALL TYPES OF CLINICAL DEPRESSION

Augmentation versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD) 

The Stanford Depression Research Clinic is seeking people with major depressive disorder (MDD) to participate in a new research study. If you are between the ages of 18 and 80, currently depressed and have a history of trying at least one antidepressant medication you may be eligible.

This study involves comparing three treatment arms:

1.  Adding Abilify® to current antidepressant medication

2.  Adding Repetitive Transcranial Magnetic Stimulation (rTMS) to current antidepressant medication

3.  Switching your current antidepressant medication to Effexor® Extended Release

These three treatments are approved by the FDA to treat TRD.  If enrolled, this study involves 9 visits over 12 weeks.

If you are currently taking an antidepressant medication that is only partially helping your depression, please contact us to learn more about our current research.

 Participants will receive compensation for their time.

If you are interested in participating or learning more about the study, please call (650) 723-8330 or email depressionresearch@med.stanford.edu.

For further details, please see the following link:  https://clinicaltrials.gov/ct2/show/NCT02977299

Identifying Biological Markers for Severe Depression

 

The primary objective of this study is to investigate the biological components of major depression.

 

We are particularly interested in genetic variation and how it contributes to cortisol (because cortisol is higher in severe depression than miild depression or healthy controls) and how it contributes to clinical symptoms, especially suicidal ideation/behavior and psychosis. 

 

We hope to learn whether there are genetic factors common in depression and their role in symptom presentation, particularly suicidality and psychosis. We aim to better understand the mechanisms of neurocognitive, physiologic and genetic dysfunction in Psychotic Depression and Non-psychotic Depression.

 

 

We are focusing on understanding the relationship of genetics to specific aspects of the HPA (hypothalamic-pituitary-adrenal) axis dysregulation in depression. With this knowledge we hope to gain a better understanding and ability to treat clinical symptoms, suicide ideation/behavior, and psychosis in persons with Major Depressive Disorder.

 

Enrolling now at Stanford University, Cornell Medical Center, and University of California at Irvine. 

 

If you are interested in participating or learning more about the study, please call (650) 723-8330 or email depressionresearch@med.stanford.edu.

 

For further details, please see the following link:

https://clinicaltrials.gov/ct2/show/NCT01831882

A Randomized, Sham-Controlled Trial of the Safety and Effectiveness of Neurostar Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents

 

Clinical study investigating a non-drug, non-invasive treatment for depression.

Teen/Young Adult Non-Drug Depression Study 

NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar TMS Therapy is only available by prescription.

Now recruiting (ages 12-21)

• FDA-cleared device for treatment of depression for adult patients who have not benefitted from prior antidepressant medication

• Magnetic pulses target key areas of the brain that may be underactive in patients with depression

• Technology is similar to magnetic resonance imaging (MRI)

• Free from side effects often associated with antidepressant medications

• NeuroStar TMS Therapy can be conducted right in the doctor’s office

If you are interested in participating or learning more about the study, please call (650) 723-8330 or email depressionresearch@med.stanford.edu.

For further details, please see the following link: https://clinicaltrials.gov/ct2/show/NCT02586688 and for an explanation of TMS by NeuroStar, please see the following link: https://www.youtube.com/watch?v=aLuRmicCYPE.

DOUBLE BLIND, CROSS-OVER TRIAL OF KETAMINE THERAPY PLUS OR MINUS NALTREXONE IN TREATMENT RESISTANT DEPRESSION (TRD)

We are doing this research study to find out if the opioid properties of Ketamine are responsible for its antidepressant effects. 

Ketamine is approved by the U.S. Food and Drug Administration (FDA) to be used with other drugs for anesthesia and as a pain reliever during procedures. However, Ketamine is not approved by the FDA to treat depression.  

This research study will use either Naltrexone to block the opioid mechanism of Ketamine or a placebo, containing no drug, to study if the results are due to Ketamine’s opioid properties or other reasons.  

Naltrexone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of detoxifying formerly opioid-dependent individuals. Placebos are used in research studies to see if the results are due to a drug or other reasons. Placebos are pills that contain no drug.

Under close supervision and monitoring by the study clinicians, eligible subjects will receive two infusions of Ketamine 0.5mg/kg divided into two phases; during each of the phases participants will also receive either a Naltrexone 50mg tablet or a placebo tablet. 

This research study is expected to take approximately 2 years to complete with at least 8 weeks of active participation by each participant.  During this time, participants will make 10 study visits to Stanford University in addition to completing two phone assessments 14 days after each infusion.

Participation is confidential and compensation is provided. If you are interested in participating or learning more about the study, please call (650) 723-8330 or email depressionresearch@med.stanford.edu.

For further details, please see the link: https://clinicaltrials.gov/ct2/show/NCT02911597

Current studies led by Dr. Nolan Williams, of the Brain Stimulation Laboratory, can be viewed below. 

 

BRAIN STIMULATION LABORATORY http:med.stanford.edu/bsl/about.html

 

1) Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia http://med.stanford.edu/bsl/research.html

2) Double Blind, Cross-Over Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD) - http://med.stanford.edu/bsl/research.html

3) Accelerated Theta Burst in Treatment Resistant Depression: A Dose Finding and Biomarker Study - http://med.stanford.edu/bsl/research.html

4) Establishing Imaging Biomarkers for Spaced Theta Burst Stimulation - http://med.stanford.edu/bsl/research.html

Current Studies (Not actively recruiting)

A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment (Schatzberg)

A Long-term Follow-Up Study for the Evaluation of Patients who have a Deep Brain Stimulation System for the Adjunctive Treatment of Major Depressive Disorder (DeBattista)

A Pilot study of Self-Defense Training in Women with Trauma (Keller)

Past Research Studies

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) (DeBattista)

A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering from a Major Depressive Disorder (MDD) and Having Had – Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic (DeBattista)

Radiosurgical Neuromodulation for Refractory Depression (Solvason)

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants. (DeBattista)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 versus Placebo, as Adjunctive Therapy in Patients with Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment (DeBattista)

A Randomized, Parallel-group, Sham-controlled, Multisite Study to Evaluate the Efficacy and Safety of the Neurostar® Transcranial Magnetic Stimulation Clinical Research System in Patients with Major Depressive Disorder (Solvason)

An Open Label, Multisite Study to Evaluate the Efficacy and Safety of the Neurostar® Transcranial Magnetic Stimulation Clinical Research System in Patients with Major Depressive Disorder (Solvason)

A Twelve Month, Open-Label, Safety Trial of Fliberanserin 50 Milligrams to 100 Milligrams Daily in Women with Hypoactive Sexual Desire Disorder (DeBattista)

A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 25 Milligrams Twice Daily and 50 Milligrams Once Daily and Twice Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in North America. (DeBattista)

Ropinerole CR as an Adjunctive Agent in the Treatment of Major Depression (DeBattista)

A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy in Subjects with Depression Treatment Failure. (DeBattista)

Quantitative Characterization of Insulin Resistance in Patients with Bipolar Disorder Treated with Atypical Antipsychotic Medication: Effect of Treatment with an Oral Hypoglycemic Agent (Solvason)

A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects with Major Depressive Disorder (DeBattista)

A Double-Blind, Placebo-Controlled Study of Mifepristone in Patients with Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT) (Solvason)

Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits following Unilateral ECT for the Treatment of a Severe Major Depressive Episode (Solvason)

An 8-week, randomized, double blind, fixed dosage, placebo-controlled, parallel group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52 week, open-label extension (DeBattista)

International Study to Predict Optimised Treatment in Depression. (DeBattista)

Neurobiological and Cognitive Comparison of Psychotic Major Depression, Schizoaffective Disorder, Schizophrenia, and Non Psychotic Major Depression (Keller)